Valens Company to Begin Trading on the Nasdaq Capital Market
Common shares are expected to start trading tomorrow on December 9, 2021, under the ticker “VLNS”
KELOWNA, BC, December 8, 2021 / CNW / – La Compagnie Valens inc. (TSX: VLNS) (Nasdaq: VLNS) (the âCompanyâ âThe Valens Companyâ or âValensâ), a leading manufacturer of cannabis products, announces that the Company’s application to list its common shares in the Nasdaq Capital Market (âNasdaqâ) has been approved. The common shares of the Company (the âCommon Sharesâ) are expected to begin trading on the Nasdaq under the symbol âVLNSâ on December 9, 2021.
The common shares of Valens will continue to be listed and traded on the Toronto Stock Exchange (TSX) under the symbol “VLNS”. The Company’s shares will continue to trade on the OTCQX under the symbol “VLNCD” until the start of trading on the Nasdaq. Shareholders are under no obligation to take any action following the bullish listing and the change of symbol.
Tyler robson, Chief Executive Officer and Chairman of The Valens Company said, âOur listing on Nasdaq represents another important milestone that reflects our commitment to all of our shareholders as we continue to advance our global growth initiatives by capitalizing on the legalization of cannabis in the world and strengthen our corporate governance. I am extremely proud of our team and the platform we have built here in Canada. Looking to the future, we will continue to build a company focused on product innovation and advancing our intellectual property to create products that consumers love. Listing on Nasdaq is the next step in our capital markets strategy. We believe that this listing will allow Valens and its shareholders better access to liquidity, increased visibility of the company and a broader shareholder base, with the aim of creating long-term shareholder value. “
Listing of the Company on Nasdaq remains subject to satisfaction of all applicable listing and regulatory requirements. At the same time as this listing on the Nasdaq, the ordinary shares of Valens will become DWAC / FAST eligible for US shareholders.
In Valens, it’s Personal.
About the company Valens
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the goodness of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to the world-class product development, manufacture and marketing of packaged cannabis consumer products. The high-quality products of the company Valens are formulated for the medical consumption, health and wellness and leisure segments, and are offered in all categories of cannabis products with an emphasis on quality. and innovation. The Company also manufactures, distributes and sells a wide range of CBD products in United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia via its subsidiary Valens Australia. In partnership with brands, consumer packaged goods companies and licensed cannabis producers around the world, the company continues to develop its diverse product portfolio in line with the evolving preferences of cannabis consumers in key markets. . Through Valens labs, the Company sets the standard in cannabis testing and research and development with from Canada The only ISO17025 accredited analytical services laboratory named a Center of Excellence in Plant-Based Science by partner and global scientific leader Thermo Fisher Scientific. Find out more about The Valens Company at http://www.thevalenscompany.com.
Notice Regarding Forward-Looking Statements
All information included in this press release, including any information regarding future financial or operational performance and other statements by The Valens Company that express management’s expectations or estimates regarding future performance, other than statements by historical facts, constitute forward-looking or forward-looking information – forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans for the future. Whenever possible, words such as “plans”, “expect”, “forecast”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predict”, “foresee”, “establish”, “believe”, “intend”, “the capacity to”, or statements that certain actions, events or results “could”, “should”, “could”, “could “,” Could “,” could “, or are” likely “to be taken, to occur or to be achieved, or the negative of these words or other variations thereof, have been used to identify this forward-looking information. Specific forward-looking statements include, without limitation, any disclosure regarding future results of operations, future results of transactions, economic conditions and planned action plans. Investors and others are advised that there is not necessarily a correlation between the number of SKUs manufactured and shipped and revenue and profit, and that this information should not be relied on unduly.
Risks and uncertainties that may affect forward-looking statements include, but are not limited to, Canadian regulatory risk, Australian regulatory risk, US regulatory risk, prohibitions on crossing the border and traveling to the United States, uncertainties, effects and responses to the COVID-19 pandemic, dependence on licenses, expansion of facilities, competition, dependence on the cannabis supply and dependence on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, modification of laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavorable consumer advertising or perception, product liability s, intellectual property risks, product recalls, difficulties with forecasting, growth management and litigation, many of which are beyond Compagnie de Valens’ control. For a more complete discussion of the risks incurred by The Valens Company, and which may cause The Valens Company’s actual financial results, performance or achievements to differ materially from the estimated future results, performance or achievements expressed or implied by the forward-looking information or forward-looking statements, please refer to the most recent annual information form of The Valens Company filed with the Canadian securities regulatory authorities at www.sedar.com or on The Valens Company website at www.thevalenscompany.com. The risks described in this Annual Information Form are incorporated by reference herein. Although the forward-looking statements contained herein reflect the current beliefs of management and reasonable assumptions based on information available to management at the date hereof, The Valens Company cannot be certain that actual results will be consistent with such information. prospective. The Valens Company cautions you not to place undue reliance on these forward-looking statements. Valens disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as an offer to sell or a solicitation to buy or sell securities of The Valens Company.
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-valens-company-to-begin-trading-on-nasdaq-capital-market-301440651.html
SOURCE La Compagnie Valens Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/08/c2029.html